CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Caliway Biopharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Caliway Biopharmaceuticals Co Ltd
Phone: +886 226971355p:+886 226971355 NEW TAIPEI, 221  Taiwan Ticker: 69196919
Business Summary
Caliway Biopharmaceuticals Co Ltd is a Taiwan-based company mainly engaged in the sale of health food, the development of drugs and technical consulting. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. It is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The Company's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board LuhuiXu 10/22/2012 10/22/2012
Chief Executive Officer, Chief Research & Development Officer, Director YufangLing 10/22/2012 10/22/2012
Corporate Governance Officer YanmiaoChen 1/1/2024 1/1/2024
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 139,324,786 (As of 3/29/2024)
Stock Exchange: TPO
Fax Number: +886 226972508


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024